Gene Expression Profile of Human Prostate Cell Lines (+/-CD82) through Microarray Analysis

Presentation Type

Oral and/or Visual Presentation

Presenter Major(s)

Cell and Molecular Biology

Mentor Information

Suganthi Sridhar, sridhars@gvsu.edu

Department

Biomedical Sciences

Location

Kirkhof Center 2263

Start Date

13-4-2011 1:30 PM

End Date

13-4-2011 2:00 PM

Abstract

KAI1/CD82, a member of tetraspanin super family, is a prostate tumor metastasis suppressor gene. CD82 expression is either decreased or completely lost during tumor progression and has been identified in several other cancers as well. The exact mechanism by which CD82 regulates metastasis suppression is still unclear. Microarray studies done previously in our lab on prostate cancer cell lines (PC3; +/- CD82), have identified genes regulated by CD82. Alternatively, we performed microarrays on normal prostate cell lines (PEC 31), along with another set of PC3 tumor cell lines (+/- CD82) to compare the results observed from our previous arrays. The 100 most common and significant genes from all three arrays were compared and the top ten genes identified to be involved in metastasis are currently being validated by qPCR protocols. Results from these studies will allow us to identify the genes and/ proteins regulated by CD82, identify downstream signaling pathways and decipher a role for CD82 in metastasis tumor suppression.

This document is currently not available here.

Share

COinS
 
Apr 13th, 1:30 PM Apr 13th, 2:00 PM

Gene Expression Profile of Human Prostate Cell Lines (+/-CD82) through Microarray Analysis

Kirkhof Center 2263

KAI1/CD82, a member of tetraspanin super family, is a prostate tumor metastasis suppressor gene. CD82 expression is either decreased or completely lost during tumor progression and has been identified in several other cancers as well. The exact mechanism by which CD82 regulates metastasis suppression is still unclear. Microarray studies done previously in our lab on prostate cancer cell lines (PC3; +/- CD82), have identified genes regulated by CD82. Alternatively, we performed microarrays on normal prostate cell lines (PEC 31), along with another set of PC3 tumor cell lines (+/- CD82) to compare the results observed from our previous arrays. The 100 most common and significant genes from all three arrays were compared and the top ten genes identified to be involved in metastasis are currently being validated by qPCR protocols. Results from these studies will allow us to identify the genes and/ proteins regulated by CD82, identify downstream signaling pathways and decipher a role for CD82 in metastasis tumor suppression.